Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serge Muyldermans

Showing results (1-10 of 231) with videos related to

Pageof 24
Sort By:
Annual Review of Animal Biosciences|November 25, 2020
Applications of NanobodiesSerge Muyldermans
Annual Review of Biochemistry|March 19, 2013
Nanobodies: natural single-domain antibodiesSerge Muyldermans
The FEBS Journal|August 12, 2020
A guide to: generation and design of nanobodiesSerge Muyldermans
Methods in Molecular Biology (Clifton, N.J.)|August 14, 2012
Introduction to heavy chain antibodies and derived NanobodiesCécile Vincke, Serge Muyldermans
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 6, 2019
The Therapeutic Potential of NanobodiesIvana Jovčevska, Serge Muyldermans
Current Opinion in Immunology|February 29, 2016
Distinct antibody species: structural differences creating therapeutic opportunitiesSerge Muyldermans, Vaughn V Smider
Annals of Laboratory Medicine|June 10, 2021
Application of Single-Domain Antibodies ("Nanobodies") to Laboratory DiagnosisTahir S Pillay, Serge Muyldermans
Biotechnology Journal|September 11, 2015
Development of a high affinity Affibody-derived protein against amyloid β-peptide for future Alzheimer's disease therapyErwin De Genst, Serge Muyldermans
Current Opinion in Biotechnology|August 25, 2011
Recent developments in engineering and delivery of protein and antibody therapeuticsLuis Ángel Fernández, Serge Muyldermans
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 17, 2005
A synthetic camel anti-lysozyme peptide antibody (peptibody) with flexible loop structure identified by high-resolution affinity mass spectrometryAndreas Marquardt, Serge Muyldermans, Michael Przybylski
Pageof 24

Showing results (1-10 of 231) with videos related to

Sort By:
Pageof 24
Annual Review of Animal Biosciences|November 25, 2020
Applications of NanobodiesSerge Muyldermans
Annual Review of Biochemistry|March 19, 2013
Nanobodies: natural single-domain antibodiesSerge Muyldermans
The FEBS Journal|August 12, 2020
A guide to: generation and design of nanobodiesSerge Muyldermans
Methods in Molecular Biology (Clifton, N.J.)|August 14, 2012
Introduction to heavy chain antibodies and derived NanobodiesCécile Vincke, Serge Muyldermans
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 6, 2019
The Therapeutic Potential of NanobodiesIvana Jovčevska, Serge Muyldermans
Current Opinion in Immunology|February 29, 2016
Distinct antibody species: structural differences creating therapeutic opportunitiesSerge Muyldermans, Vaughn V Smider
Annals of Laboratory Medicine|June 10, 2021
Application of Single-Domain Antibodies ("Nanobodies") to Laboratory DiagnosisTahir S Pillay, Serge Muyldermans
Biotechnology Journal|September 11, 2015
Development of a high affinity Affibody-derived protein against amyloid β-peptide for future Alzheimer's disease therapyErwin De Genst, Serge Muyldermans
Current Opinion in Biotechnology|August 25, 2011
Recent developments in engineering and delivery of protein and antibody therapeuticsLuis Ángel Fernández, Serge Muyldermans
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 17, 2005
A synthetic camel anti-lysozyme peptide antibody (peptibody) with flexible loop structure identified by high-resolution affinity mass spectrometryAndreas Marquardt, Serge Muyldermans, Michael Przybylski
Pageof 24